10 June 2022 - The US FDA is quicker to approve new oncology drugs compared with the EMA, according to a study published 10 June in JAMA Network Open.

Mark P. Lythgoe, MBBS, of Imperial College London, and colleagues performed a cross-sectional study of 89 oncology drugs that were approved in the US and Europe between 2010 and 2019, analysing how long each drug was reviewed, when the drug was submitted for marketing authorisation, whether it had received accelerated approval or conditional marketing authorisation, and the drug’s regulatory approval date with each agency.

Read Regulatory Affairs Professional Society article